12:08 PM EDT, 07/18/2025 (MT Newswires) -- CareDx ( CDNA ) said Friday it has released a proposed draft Local Coverage Determination on molecular testing for solid organ allograft rejection.

There is no change in current coverage and the draft policy is open for comment through Aug. 31, the company said. The proposal also introduces a bundled payment model for surveillance testing.

The company said it is reviewing the draft policy and plans to provide additional information at its earnings call on Aug. 6.

Shares of CareDx ( CDNA ) were up more than 3% in recent trading.

Price: 12.22, Change: +0.41, Percent Change: +3.47